secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001493152-25-021748
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid Diagnostics Q3 revenue $1.2M, loss $0.10/share; key Medicare coverage step from unanimous CAC expert support
--------------------------------------------------------------------------------

- Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
- GAAP net loss $10.4M ($0.10/share); non-GAAP adjusted loss $10.3M ($0.10/share).
- Cash $47.3M after $27M public offering; runway extended through 2026.
- MolDx CAC meeting on Sept 4: medical experts unanimously supported Medicare coverage for EsoGuard.
- Appointed Danielle Scelfo as SVP Market Access to lead payor engagement and coverage expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/0001493152-25-021748-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315225021748/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-021748

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer